RESOURCES

Where research scientists come to find up to date resources on antibody discovery against challenging membrane protein targets.

Publications

500+ publications and patents

Featured Publications

Antibody specificity against highly conserved membrane protein Claudin 6 driven by single atomic contact point Screnci et al. 2022 iScience 25, 105665

Read More

Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape – Ku et al. 2021 Nature Communications 12, 469

Read More
Antigenicity, stability, and reproducibility of Zika reporter virus particles for long-term applications – Whitbeck et al. 2020 PLoS Neglected Tropical Diseases 14, e0008730

Read More

Additional publications by Integral Molecular

Case Studies

Featured Case Studies

AdAlta – Learn how Lipoparticles enabled the discovery of a CXCR4 clinical stage i-body
Read More
Novartis – Understanding mechanism of action: how a biparatopic CXCR2 nanobody inhibits with high potency and efficacy
Read More
Cabaletta Bio – Learn how the MPA was used to screen specificity of a novel T-cell therapeutic for a successful IND submission Read More
  • Claudin 6 – Isolation of highly specific MAbs against the tight junction protein Claudin 6 for solid tumors
  • GLUT4 – Discovery of state-specific antibodies against SLC2A4 (GLUT4), a complex 12-TM transporter, for diabetes
  • P2X7 – Agonist and antagonist MAbs targeting the P2X7 ion channel for autoimmune disorders
  • CB1 – Discovery of antagonist MAbs against the GPCR CB1 for treating NASH liver disease
  • GPCR – An agonist antibody targeting a challenging GPCR target
  • Ablynx – Learn how Lipoparticles rescued a CX3CR1 discovery campaign and enabled a clinical stage antibody
  • AdAlta – Learn how Lipoparticles enabled the discovery of a CXCR4 clinical stage i-body
  • Argenx – Learn how Lipoparticles were used to isolate antibodies with diverse epitopes against the GPCR glucagon receptor
  • Novartis – Understanding mechanism of action: how a biparatopic CXCR2 nanobody inhibits with high potency and efficacy
  • Merck – Epitope mapping of conformation specific RSV F antibodies
  • Covagen – Using epitope data to distinguish a novel bispecific HER2 antibody from existing therapeutics
  • Cabaletta Bio – Learn how the MPA was used to screen specificity of a novel T-cell therapeutic for a successful IND submission
  • Totient – Learn how Totient (now AbSci) used the MPA to deorphan intratumoral antibodies and identify potential oncology targets
  • AboundBio – Learn how the MPA was used to rapidly screen the specificity of a SARS-CoV-2 neutralizing antibody for therapeutics
  • FairJourney – See how FairJourney established that their antibodies against CXCR4 do not demonstrate off-target binding
  • Deorphaning – Learn how the MPA was used to deorphan panels of antibodies obtained through phenotypic screening
  • Takeda – Learn how dengue and Zika RVPs enabled clinical progression of Takeda’s Zika and dengue vaccines
  • University of Pittsburgh – Learn how researchers used SARS-CoV-2 RVPs to screen their nanobodies for virus-neutralizing activity, results published in Science
  • PPD– Learn how SARS-CoV-2 RVPs can be used for sera screening and immunogenicity assays.
  • Immunome – Learn how SARS-CoV-2 RVPs facilitated testing of a therapeutic antibody cocktail and enabled its progression to the clinic

Webinars

Featured Webinars

Harnessing Divergent Species to Access Difficult and Conserved Antibody Targets


Watch Video

Specificity Testing of Antibody and CAR-T Cell Therapies for IND Using the Membrane Proteome Array

Watch Video
Innovative Research Tools to Combat Biological Threats


Watch Video